Fludeoxyglucose ( DrugBank: Fludeoxyglucose )

3 diseases

ID	Disease name (Link within this page)	Number of trials
84	Sarcoidosis	1
85	Idiopathic interstitial pneumonia	1
88	Chronic thromboembolic pulmonary hypertension	1

84. Sarcoidosis

Clinical trials : 149 / Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-001815-11-FI (EUCTR)	19/04/2016	29/12/2015	PET imaging of pulmonary sarcoidosis	Imaging of active granulomas with [18F]FDG and selected inflammatory PET tracers in pulmonary sarcoidosis	Pulmonary sarcoidosis with active garnulomas in the lungs. The diagnosis is based on the clinical evidence or biopsy. MedDRA version: 18.1;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]	Product Name: 18F-fluorodeoxyglucose Product Code: FDG INN or Proposed INN: FLUORINE (18F) FLUDEOXYGLUCOSE Product Name: C11-methionine INN or Proposed INN: L-methionine Other descriptive name: L-METHIONINE ([11C]METHYL) Product Name: 68Ga-DOTANOC INN or Proposed INN: DOTANOC Other descriptive name: DOTANOC	Turku PET Centre	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Finland

Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-020223-44-AT (EUCTR)	03/08/2010	29/06/2010	(18)F-FDG PET/CT in patients with idiopathic interstitial pneumonias: correlation of tracer uptake and histological findings, and texture-based recognition of usual interstitial pneumonia	(18)F-FDG PET/CT in patients with idiopathic interstitial pneumonias: correlation of tracer uptake and histological findings, and texture-based recognition of usual interstitial pneumonia	Interstitial lung disease of unknown etiology	Trade Name: (18)F-FDG Product Name: (18)F-FDG INN or Proposed INN: FLUORINE (18F) FLUDEOXYGLUCOSE	Medizinische Universität Wien, Univ.Klinik f.Radiodiagnostik	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Austria

Clinical trials : 157 / Drugs : 107 - (DrugBank : 22) / Drug target genes : 14 - Drug target pathways : 54

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-000347-14-ES (EUCTR)	16/06/2016	17/05/2016	Comparative study between patients with pulmonary hypertension and healthy subjects detecting pulmonary cell changes by FDG PET imaging	Cell proliferation in pulmonary hypertension: mollecular imaging detection by FDG PET. Comparative study between patients and healthy subjects	Pulmonary artery hypertension and thromboembolic chronic pulmonary hypertension MedDRA version: 19.0;Level: LLT;Classification code 10037405;Term: Pulmonary hypertension primary;System Organ Class: 100000004855 MedDRA version: 19.0;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]	Trade Name: Barnascan Product Name: BARNASCAN INN or Proposed INN: FLUDEOXYGLUCOSE Other descriptive name: FLUDEOXYGLUCOSE	IDIBAPS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Spain